title: Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
abstract: The 2003 guidelines for the management of hyperparathyroidism in chronic kidney disease compiled by the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation (NKF-K/DOQI) were formulated on the basis of work published up until 2001. Since then, new drugs (e.g. calcimimetics and lanthanum carbonate) have become available, and others (e.g. sevelamer, nicotinamide and paricalcitol) have been more stringently clinically evaluated. Because of these advancements, a reappraisal of the 2003 guidelines is justified. In this article we critically review the following recommendations of the NKF-K/DOQI: (i) routine use of 1.25 mmol/l (5.0 mg/dl) dialysate calcium and 1 alphaOH-vitamin D derivatives; (ii) limitation of the maximal daily dose of calcium-based oral phosphate binders to 1.5 g of elemental calcium; and (iii) not correcting vitamin D insufficiency in dialysis patients.
authors.affiliation: Department of Nephrology Internal Medicine, Amiens University Hospital, Jules Verne University of Picardy, Amiens, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Monge
authors.forename: Irina
authors.initials: I
authors.lastname: Shahapuni
authors.forename: Roxana
authors.initials: R
authors.lastname: Oprisiu
authors.forename: Najeh
authors.initials: N
authors.lastname: El Esper
authors.forename: Philippe
authors.initials: P
authors.lastname: Morinière
authors.forename: Ziad
authors.initials: Z
authors.lastname: Massy
authors.forename: Gabriel
authors.initials: G
authors.lastname: Choukroun
authors.forename: Albert
authors.initials: A
authors.lastname: Fournier
mesh_terms: D001847:Bone Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D001842:Bone and Bones / Q000378:metabolism; D002113:Calcification, Physiologic; D002118:Calcium / Q000008:administration & dosage / Q000097:blood*; D019317:Evidence-Based Medicine; D015312:Hemodialysis Solutions / Q000737:chemistry*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism* / Q000628:therapy; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis; D014808:Vitamin D Deficiency / Q000188:drug therapy* / Q000209:etiology
chemical_list: D015312:Hemodialysis Solutions; D002118:Calcium